CERE - Cerevel Therapeutics Holdings, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Currency in USD

Valuation measures4

Market cap (intra-day) 4.92B
Enterprise value 4.46B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)9.60
Enterprise value/revenue N/A
Enterprise value/EBITDA -11.30

Trading information

Stock price history

Beta (5Y monthly) 1.48
52-week change 327.82%
S&P500 52-week change 31.77%
52-week high 341.46
52-week low 322.10
50-day moving average 328.08
200-day moving average 329.15

Share statistics

Avg vol (3-month) 3601.51k
Avg vol (10-day) 3426.75k
Shares outstanding 5156.83M
Implied shares outstanding 6N/A
Float 858.67M
% held by insiders 117.56%
% held by institutions 188.81%
Shares short (14 May 2023) 44.72M
Short ratio (14 May 2023) 47.02
Short % of float (14 May 2023) 410.72%
Short % of shares outstanding (14 May 2023) 43.01%
Shares short (prior month 13 Apr 2023) 44.96M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)30 Mar 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-31.87%
Return on equity (ttm)-81.31%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -389.76M
Net income avi to common (ttm)-387.5M
Diluted EPS (ttm)-2.48
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)826.99M
Total cash per share (mrq)5.27
Total debt (mrq)438.71M
Total debt/equity (mrq)101.62
Current ratio (mrq)13.35
Book value per share (mrq)2.75

Cash flow statement

Operating cash flow (ttm)-320.46M
Levered free cash flow (ttm)-179.43M